Shopping Cart
Remove All
Your shopping cart is currently empty
GNE-5729 is a positive allosteric modulator of NMDAR with the advantage of crossing the blood-brain barrier and being orally available, with EC50 values of 37 nM, 4.7 μM and 9.5 μM for GluN2A, GluN2C and GluN2D, respectively, and can be used for the study of neurological and psychiatric disorders.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $263 | - | In Stock | |
| 5 mg | $645 | - | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,980 | - | In Stock | |
| 50 mg | $3,180 | - | In Stock | |
| 100 mg | $4,300 | - | In Stock |
| Description | GNE-5729 is a positive allosteric modulator of NMDAR with the advantage of crossing the blood-brain barrier and being orally available, with EC50 values of 37 nM, 4.7 μM and 9.5 μM for GluN2A, GluN2C and GluN2D, respectively, and can be used for the study of neurological and psychiatric disorders. |
| Targets&IC50 | GluN2A:37 nM (EC50), GluN2C:4.7 μM (EC50), GluN2D:9.5 μM (EC50) |
| In vitro | GNE-5729 is a brain-penetrant positive allosteric modulator of NMDA receptors, showing selective enhancement of GluN2A activity (EC₅₀ = 37 nM), with much weaker effects on GluN2C and GluN2D subtypes (EC₅₀ = 4.7 μM and 9.5 μM, respectively) [1]. |
| Synonyms | GNE5729 |
| Molecular Weight | 428.2 |
| Formula | C17H10Cl2F3N5O |
| Cas No. | 2026635-66-3 |
| Smiles | ClC1=C(N2C(=NC(CN3N=C(C(F)(F)F)C=C3Cl)=CC2=O)C=C1)[C@H]4[C@H](C#N)C4 |
| Relative Density. | 1.71 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (186.83 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.71 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.